FLUPHENAZINE HYDROCHLORIDE: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Pharm Assoc	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	CONCENTRATE;ORAL	074725	ANDA	PAI Holdings, LLC dba PAI Pharma	0121-0653-04	120 mL in 1 BOTTLE, DROPPER (0121-0653-04)	2010-09-01
Pharm Assoc	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	ELIXIR;ORAL	040146	ANDA	PAI Holdings, LLC dba PAI Pharma	0121-0654-02	60 mL in 1 BOTTLE (0121-0654-02)	2010-08-31
Pharm Assoc	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	ELIXIR;ORAL	040146	ANDA	PAI Holdings, LLC dba PAI Pharma	0121-0654-16	473 mL in 1 BOTTLE (0121-0654-16)	2010-08-31
Fresenius Kabi Usa	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	INJECTABLE;INJECTION	089556	ANDA	Fresenius Kabi USA, LLC	63323-281-10	1 VIAL in 1 BOX (63323-281-10) / 10 mL in 1 VIAL	2010-12-28
Ajanta Pharma Ltd	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	TABLET;ORAL	217410	ANDA	Ajanta Pharma USA Inc.	27241-252-01	100 TABLET in 1 BOTTLE (27241-252-01)	2023-01-05
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply chain for fluphenazine hydrochloride, a first-generation antipsychotic. It identifies leading manufacturers, examines key patents, and outlines regulatory considerations impacting market access. The analysis provides critical intelligence for R&D and investment decisions within the pharmaceutical sector.

Who are the Primary Manufacturers of Fluphenazine Hydrochloride?

Several pharmaceutical ingredient manufacturers globally produce fluphenazine hydrochloride. Production volume and market share are concentrated among a limited number of entities, primarily in Asia. These manufacturers supply the active pharmaceutical ingredient (API) to formulators for finished dosage forms.

Key manufacturers include:

Hangzhou Apex Chemical Co., Ltd. (China): A significant producer of APIs, including fluphenazine hydrochloride. They operate under GMP standards and supply to international markets. Their capacity and pricing are competitive factors in the global supply chain.
Loba Chemie Pvt. Ltd. (India): This company is a well-established supplier of laboratory chemicals and APIs. Loba Chemie offers fluphenazine hydrochloride, adhering to various pharmacopeial standards for purity and quality.
Tianjin Hegang Pharmaceutical Co., Ltd. (China): Another major Chinese API manufacturer with a portfolio that includes antipsychotic medications. Hegang Pharmaceutical focuses on large-scale production to meet global demand.
Thermo Fisher Scientific (USA/Global): While more broadly known for laboratory equipment and research chemicals, Thermo Fisher Scientific also distributes pharmaceutical ingredients, including fluphenazine hydrochloride, often for research and development purposes, as well as for smaller-scale manufacturing. They leverage a global distribution network.

The competitive landscape is characterized by price sensitivity and stringent quality control requirements. Manufacturers must meet pharmacopeial standards such as USP (United States Pharmacopeia) and EP (European Pharmacopoeia).

What is the Patent Landscape for Fluphenazine Hydrochloride?

Fluphenazine hydrochloride itself is a well-established drug. Its original patents have long expired. However, patents relating to fluphenazine hydrochloride can exist for:

New Synthesis Methods: Novel or improved chemical processes for manufacturing the API.
Formulations: New drug delivery systems, such as extended-release formulations, depot injections, or novel tablet compositions.
Combinations: Pharmaceutical compositions containing fluphenazine hydrochloride in combination with other active pharmaceutical ingredients.
Therapeutic Uses: New medical indications or treatment regimens for the drug.

Key Patent Observations:

Genericity: The core molecule is off-patent, allowing for generic manufacturing by multiple companies.
Process Patents: While original synthesis routes are public knowledge, companies may patent incremental improvements to existing processes, aiming for higher yields, reduced impurities, or cost efficiencies. These patents can provide a competitive edge in API manufacturing.
Formulation Innovation: Significant patent activity often centers on improved formulations. For fluphenazine hydrochloride, this has historically included:
- Depot Injections: Formulations designed for long-acting administration, such as fluphenazine decanoate and enanthate, which are esters of fluphenazine. These are administered intramuscularly and are absorbed slowly, providing therapeutic effects for weeks. Patents in this area focus on the esterification process, the oil-based vehicle, and methods of administration.
- Extended-Release Oral Forms: Patents might cover specific polymer matrices, coating technologies, or pellet designs that control the rate of drug release from oral dosage forms.

Example of Patent Scope:

A patent might claim a specific process for synthesizing fluphenazine decanoate, involving a particular catalyst or reaction condition that results in higher purity or yield compared to prior art. Another patent could describe a novel microencapsulation technique for creating fluphenazine hydrochloride pellets with a defined release profile over 24 hours.

Patent Search Strategy:

Identifying relevant patents requires searching databases such as:

USPTO (United States Patent and Trademark Office)
EPO (European Patent Office)
WIPO (World Intellectual Property Organization) - PCT Database
Commercial Patent Databases (e.g., Derwent Innovation, PatSnap)

Search terms would include "fluphenazine," "fluphenazine hydrochloride," "fluphenazine decanoate," "fluphenazine enanthate," "antipsychotic," and relevant chemical structure identifiers. Keywords related to synthesis, formulation, and delivery methods are also crucial.

Patent Expiration and Generic Entry:

When formulation or process patents expire, it typically opens the door for generic manufacturers to enter the market. The timing of patent expiration directly impacts the competitive landscape and pricing. For fluphenazine decanoate and enanthate, while the fluphenazine moiety is old, patents on the specific esterification processes or unique depot formulations can still be active.

What are the Regulatory Considerations for Fluphenazine Hydrochloride?

Manufacturing and marketing fluphenazine hydrochloride, both as an API and a finished drug product, are subject to stringent regulatory oversight by health authorities worldwide. Key considerations include:

Good Manufacturing Practices (GMP): All manufacturing facilities producing fluphenazine hydrochloride API or finished drug products must comply with GMP regulations. This ensures product quality, safety, and consistency. Regulatory bodies like the FDA (U.S. Food and Drug Administration), EMA (European Medicines Agency), and others conduct inspections to verify compliance.
Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF contains confidential, detailed information about the manufacturing process, facilities, and controls for the API. This allows drug product manufacturers to reference the DMF in their marketing authorization applications without needing to disclose proprietary API information.
Pharmacopeial Standards: Fluphenazine hydrochloride must meet the specifications outlined in official pharmacopeias, such as the USP, EP, JP (Japanese Pharmacopoeia), and BP (British Pharmacopoeia). These monographs define standards for identity, purity, strength, and quality.
Marketing Authorization: Finished drug products containing fluphenazine hydrochloride require marketing authorization from the relevant health authority in each country where they are sold. This process involves submitting comprehensive data on the drug's safety, efficacy, and quality.
ANDA (Abbreviated New Drug Application): For generic versions of approved fluphenazine hydrochloride products, manufacturers typically submit an ANDA to the FDA. This application demonstrates that the generic drug is bioequivalent to the reference listed drug and meets the same quality standards.
Impurity Profiling: Regulatory agencies require thorough characterization and control of impurities in both APIs and finished drug products. Manufacturers must identify, quantify, and set limits for process-related impurities and degradation products.
Stability Studies: Extensive stability testing is required to determine the shelf-life of the API and finished drug product under various storage conditions. This data supports the proposed expiration dating.
Environmental, Health, and Safety (EHS) Regulations: Manufacturing processes must adhere to EHS regulations concerning chemical handling, waste disposal, and worker safety.

Specific Considerations for Depot Formulations:

Depot injections (fluphenazine decanoate, enanthate) present additional regulatory complexities due to their complex formulation and unique administration method.

Sterility Assurance: Parenteral products require strict aseptic processing and validation to ensure sterility.
Vehicle Characterization: The oil-based vehicle used in depot injections must be well-characterized and proven safe and effective for intramuscular administration.
Drug Release Kinetics: Detailed studies demonstrating the controlled and sustained release of the drug from the depot formulation are necessary.

The regulatory environment is dynamic, with evolving guidelines on topics like nitrosamine impurities, elemental impurities, and data integrity. Manufacturers must continuously monitor and adapt to these changes.

How is Fluphenazine Hydrochloride Priced and Marketed?

The pricing and marketing of fluphenazine hydrochloride are influenced by several factors, primarily its status as an off-patent, generic medication.

API Pricing: The price of fluphenazine hydrochloride API is largely determined by manufacturing costs, economies of scale, raw material availability, and competitive pressures among API suppliers. Manufacturers in China and India often offer the most competitive pricing due to lower labor and operational costs. Bulk purchasing agreements can also lead to significant price reductions.
Finished Dosage Form Pricing: The pricing of finished dosage forms (tablets, injections) is influenced by the cost of the API, manufacturing costs of the final product, packaging, distribution, marketing expenses, and reimbursement policies.
- Generic Competition: The presence of multiple generic manufacturers for oral formulations leads to intense price competition, driving prices down to the lowest feasible levels.
- Specialty Formulations: Long-acting injectable formulations, such as fluphenazine decanoate and enanthate, may command higher prices than oral forms due to the complexity of their manufacturing and formulation, and potentially less direct generic competition for specific ester forms or delivery technologies.
Market Segmentation:
- Institutional Markets: Hospitals and mental health facilities purchase fluphenazine hydrochloride in large volumes, often through formulary agreements and competitive bidding processes.
- Retail Pharmacy: Outpatient prescriptions are filled through retail pharmacies, where pricing is influenced by insurance formularies and pharmacy benefit manager (PBM) negotiations.
Marketing Strategies: For generic products, marketing often focuses on:
- Reliability of Supply: Ensuring consistent availability of the product.
- Quality Assurance: Highlighting adherence to pharmacopeial standards and GMP.
- Cost-Effectiveness: Emphasizing the economic benefits of generic alternatives.
- Therapeutic Equivalence: Demonstrating bioequivalence to the reference product. For branded versions or novel formulations (historically), marketing would have included direct-to-physician detailing, scientific publications, and educational programs highlighting clinical benefits and differentiating features.

Trends in the Market:

Consolidation: The generic pharmaceutical market has seen consolidation, with larger companies acquiring smaller ones to gain market share and operational efficiencies.
Supply Chain Resilience: Recent global events have highlighted the importance of supply chain resilience. Companies are increasingly diversifying their API sourcing and building stronger relationships with key suppliers.
Biosimil-like Pressure: While not a biologic, the pressure on pricing from multiple generic entrants creates a market dynamic similar to the early days of biosimilar competition, where cost becomes a primary differentiator.

The market for fluphenazine hydrochloride is mature. Growth is primarily driven by its continued use in established treatment protocols and its affordability, especially in healthcare systems with budget constraints.

Key Takeaways

Fluphenazine hydrochloride is a mature, off-patent antipsychotic API with a global supply chain dominated by manufacturers in China and India. While the core molecule is generic, patent protection can exist for novel synthesis processes, extended-release oral formulations, and particularly for long-acting injectable ester forms (decanoate, enanthate). Regulatory compliance, including GMP and pharmacopeial standards, is paramount for all suppliers and formulators. Pricing is highly competitive for oral generics, with specialty injectable formulations commanding higher prices. Market dynamics are shaped by generic competition, cost-effectiveness, and supply chain reliability.

FAQs

What is the typical purity standard for fluphenazine hydrochloride API? Fluphenazine hydrochloride API is typically required to meet pharmacopeial standards, such as those defined in the United States Pharmacopeia (USP) or European Pharmacopoeia (EP). These standards specify limits for assay (usually 98.0% to 102.0% on the dried basis), related substances (impurities), water content, and other physical and chemical characteristics.
Are there any active patents on the synthesis of fluphenazine hydrochloride? The original synthesis patents for fluphenazine hydrochloride have long expired. However, companies may hold patents on specific, improved synthetic routes that offer advantages in terms of yield, purity, cost-effectiveness, or environmental impact compared to older methods. These are typically process patents rather than composition of matter patents for the molecule itself.
What are the main differences between fluphenazine hydrochloride and its ester prodrugs like decanoate and enanthate? Fluphenazine hydrochloride is the immediate-release oral form. Fluphenazine decanoate and enanthate are ester prodrugs designed for long-acting intramuscular depot injections. They are formulated in an oil-based vehicle and are slowly hydrolyzed in the body to release active fluphenazine over a period of weeks, reducing the need for frequent dosing.
How do regulatory agencies ensure the quality of fluphenazine hydrochloride API from different manufacturers? Regulatory agencies ensure quality through several mechanisms:
- Facility Inspections: Conducting on-site inspections of manufacturing facilities to verify compliance with Good Manufacturing Practices (GMP).
- Drug Master Files (DMFs): Reviewing DMFs submitted by API manufacturers, which detail manufacturing processes, controls, and quality assurance measures.
- Pharmacopeial Standards: Mandating that the API meets the specifications outlined in official pharmacopeias.
- Post-Market Surveillance: Monitoring product quality through adverse event reporting and occasional product testing.
What impact has the emergence of atypical antipsychotics had on the market for fluphenazine hydrochloride? The emergence of atypical antipsychotics, which generally have a lower risk of certain side effects like extrapyramidal symptoms, has led to a shift in prescribing patterns. Atypical antipsychotics are now often first-line treatments. However, first-generation antipsychotics like fluphenazine hydrochloride remain important, particularly due to their cost-effectiveness, established efficacy for specific patient populations, and the availability of long-acting injectable formulations for adherence challenges. They continue to hold a significant market share, especially in resource-limited settings and for patients who respond well to them.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/drug-master-files/drug-master-files [2] European Medicines Agency. (n.d.). Good manufacturing practice (GMP). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/good-manufacturing-practice-compliance [3] United States Pharmacopeia. (n.d.). Pharmacopeial Forum. Retrieved from https://www.uspnf.com/pharmacopeial-forum [4] World Intellectual Property Organization. (n.d.). PATENTSCOPE. Retrieved from https://patentscope.wipo.int/ [5] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://patft.uspto.gov/

Suppliers and packagers for generic pharmaceutical drug: FLUPHENAZINE HYDROCHLORIDE